endogenous retrovirus group K3 member 1Genealiases: []
Q-omics provides the consensus-scored ERVK3-1 profile across patient tissues and cancer cell-line models. ERVK3-1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ERVK3-1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, ERVK3-1 RNA expression shows 20,956 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where ERVK3-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERVK3-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERVK3-1 survival associations across molecular data types. ERVK3-1 RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERVK3-1 RNA expression–survival associations across cancer types. High ERVK3-1 expression shows unfavorable associations in KIRC, ACC, LIHC and KICH, but favorable associations in BLCA and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ERVK3-1 RNA expression.
This table summarizes ERVK3-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ERVK3-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERVK3-1 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, STAD and CHOL. The HNSC box plot shows higher ERVK3-1 RNA expression in tumor versus normal tissue (log2 FC = +0.390, t-test p < 0.001).
This table shows molecular features associated with ERVK3-1 in patient tissues and cancer cell lines. In patient samples, ERVK3-1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ERVK3-1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and STOMACH.
